

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 June 2025 (05.06.2025)



(10) International Publication Number
WO 2025/117616 A1

(51) International Patent Classification:

C07D 405/14 (2006.01) A61P 35/00 (2006.01)
C07D 401/14 (2006.01) A61K 31/506 (2006.01)

(21) International Application Number:

PCT/US2024/057574

(22) International Filing Date:

26 November 2024 (26.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/603,095 27 November 2023 (27.11.2023) US
63/611,727 18 December 2023 (18.12.2023) US
63/563,922 11 March 2024 (11.03.2024) US

(71) Applicant: NIKANG THERAPEUTICS, INC. [US/US];
200 Powder Mill Road, BLDG E500, Wilmington,
Delaware 19803 (US).

(72) Inventors: YU, Zhiyong; c/o NiKang Therapeutics,
Inc., 200 Powder Mill Road, BLDG E500, Wilmington,
Delaware 19803 (US). LOU, Yan; c/o NiKang Therapeu-
tics, Inc., 200 Powder Mill Road, BLDG E500, Wilmington,
Delaware 19803 (US).

(74) Agent: RICE, Janice et al.; Squire Patton Boggs (US) LLP,
555 California Street, Suite 550, San Francisco, California
94104 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DE-
GRADING CYCLIN-DEPENDENT KINASE 2 AND CYCLIN-DEPENDENT KINASE 4 VIA UBIQUITIN PROTEASOME PATH-
WAY



(57) Abstract: The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) and Cyclin-dependent kinase 4 (CDK4) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2 and/or CDK4. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.